Metastatic breast cancer subtypes and central nervous system metastases

C. Aversa, V. Rossi, E. Geuna, R. Martinello, A. Milani, S. Redana, G. Valabrega, M. Aglietta, F. Montemurro

Research output: Contribution to journalArticlepeer-review


Background: Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. Patients and methods: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. Results: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (. p

Original languageEnglish
Pages (from-to)623-628
Number of pages6
Issue number5
Publication statusPublished - Oct 1 2014


  • BC subtypes
  • Brain metastases
  • Breast neoplasms
  • Survival outcome

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)


Dive into the research topics of 'Metastatic breast cancer subtypes and central nervous system metastases'. Together they form a unique fingerprint.

Cite this